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Abstract
The aim of the present study was to investigate in vivo whether bone morphogenetic protein-7 (BMP-7) was 
able to promote and accelerate dental implant healing at a low dose in an osteopenic environment by using 
a delayed drug-release system.
 Skeletally mature Chinese goats, having physiologically osteopenic (osteoporotic-like) facial bones, served 
as an animal model. Dental implants were provided with a delayed-release drug-delivery system and BMP-7 
was applied at three different dosages. The implants, inserted into healed extraction sockets, were removed 
1, 2 and 3 weeks after surgery. Quantification of osseointegration and formation of new bone in the peri-
implant space were measured histomorphometrically.
 Data revealed no evidence of any adverse drug effect at or near the implantation sites. After the first 
postoperative week, bone neoformation was minimal; after the second week, peri-implant bone formation 
appeared, particularly in the groups with low dosages of BMP-7. After 3 weeks, new-bone volume was the 
largest in the group with the lowest (near-physiological) dosage of BMP-7, also showing the highest efficacy 
of BMP-7. Other dosage or release modes were found to be significantly less effective.
 BMP-7 was highly efficacious in promoting and accelerating bone formation in the peri-implant space 
in a hostile osteopenic environment if released by a slow-mode mechanism over time at near physiological 
activities. Therefore, biological functionalisation of dental implants by a high-power osteogenic factor may 
improve their healing success in hostile bony environments (osteopenia, osteoporosis, bone atrophy etc.).
Keywords: Dental implant healing, osteopenia, osteoporosis, osteoinduction, bone morphogenetic protein-7, 
slow-release system, improved safety, enhanced efficacy.
*Address for correspondence: E.B. Hunziker, MD, PhD, Departments of Osteoporosis and Orthopaedic 
Surgery, Inselspital Bern University Hospital, Freiburgstrasse 3, CH-3010 Bern, Switzerland.
Telephone number: +41 794446551   Email: ernst.hunziker@dbmr.unibe.ch
Copyright policy: This article is distributed in accordance with Creative Commons Attribution Licence 
(http://creativecommons.org/licenses/by-sa/4.0/).
European Cells and Materials Vol. 41  2021 (pages 170-183)  DOI: 10.22203/eCM.v041a12                        ISSN 1473-2262
THE SLOW RELEASE OF BMP-7 AT A LOW DOSE ACCELERATES 
DENTAL IMPLANT HEALING IN AN OSTEOPENIC ENVIRONMENT
E.B. Hunziker1,*, Y. Liu2, M. Muff1, T. Haegi1, N. Shintani3 and K. Lippuner3
1 Departments of Osteoporosis and Orthopaedic Surgery, Inselspital Bern, University Hospital,
Bern, Switzerland
2 Department of Oral Implantology and Prosthetic Dentistry, Academic Centre for Dentistry Amsterdam 
(ACTA), VU University, Amsterdam, the Netherlands
3 Department of Osteoporosis, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland
Introduction
Dental implantology has developed quite rapidly 
during the past decades into a very successful clinical 
field. It was able to significantly improve patient life 
quality in all age groups (including the elderly) by 
providing safe and reproducible treatment schemes 
for a large variety of patients, thus becoming a widely 
used treatment both in dental traumatology as well 
as in a large variety of disease-associated tooth loss 
conditions (Ananth et al., 2015; Bohner et al., 2019; 
Pauletto et al., 2019). A large group of patients, in 
particular those with insufficient oral hygiene and 
with associated parodontitis problems, is considered 
at high risk of implant failure (Hasanoglu Erbasar 
et al., 2019; Pirc and Dragan, 2017). However, these 
patients can still be treated, provided that adequate 
instruction of patients is assured and that there is 
reasonable patient compliance. But there remain 
large patient groups that are confronted with higher 
failure risks of these treatment approaches, mainly 
due to problems associated with local lack of bone 
tissue [osteoporosis, osteopenia, atrophy (Bertl et al., 
2015; Radi et al., 2018)], Paget-related metabolic bone 
disorders (Alonso et al., 2017; Hammerle and Tarnow, 
2018) and also those suffering from impaired blood-
vessel formation problems [reduced angiogenesis 
activities (Pearl and Kanat, 1988)]. Another group of 
patients that are generally excluded from implant 
treatment are those subject to some specific medical 
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mimicking the growth-factor-containing mineralised 
bone matrix compartment (Hauschka et al., 1988; 
Hauschka et al., 1986; Linkhart et al., 1996). This 
enabled BMP to be exposed only to the desired cell 
populations specifically involved in bone induction 
activities. Moreover, BMP was applied at a very low 
(i.e. physiological-like) concentration to overcome 
its many undesired effects. For this purpose, a slow 
drug-release system that simulated mineralised bone 
matrix was used as a drug carrier, with the drug 
incorporated at a physiological-like concentration. 
To test this hypothesis, an experimental animal 
model with physiological osteopenic mandibulae 
and maxillae (as a paradigm for osteoporotic and 
other types of structural bone deficiencies) in the 
masticatory apparatus was used.
Materials and Methods
Experimental design
The aim of the present study was to elucidate if 
BMP-7, used in a confined compartment of a slow 
drug-release system and at low concentration, was 
able to enhance bone formation around dental 
implants and accelerate their osseointegration in an 
osteopenic environment. For this purpose, a recently 
developed experimental implant type was used 
(Hunziker et al., 2018) that allows for quantitative 
bone formation assessment and osseointegration 
over time of bioactive implant-surfaces. Acid-etched 
and sand-blasted titanium implants were used 
and coated with a calcium phosphate (CaP)-based 
slow-release system. The implants had large peri-
implant chambers (Fig. 1) to be filled with new 
bone. The implants were inserted into the edentulate 
maxillae of adult goats that characteristically 
have physiologically (inherent to this animal, i.e. 
not experimentally induced) osteopenic bones of 
the masticatory apparatus (Caulier et al., 1997). A 
physiological model of osteoporosis was chosen 
to avoid secondary, experimentally induced bone 
formation problems (He et al., 2011). 48 goats were 
used and 3 different post-operative time points 
analysed (i.e. 1, 2 and 3 weeks after surgery) for 
a total of 54 implants placed per time point (i.e. 4 
implants per animal; Table 1). The implants with 
surrounding bone tissue were excised after surgery 
for histomorphometrical analysis of pertinent 
stereological estimators, namely, the volume of 
neo-formed bone within the chamber space of the 
implant and the bone-to-implant contact (BIC) area. 
During specimen excision, the surrounding hard and 
soft tissues in the immediate vicinity and at larger 
distances were carefully inspected and checked for 
untoward effects such as cyst formation and ectopic 
ossification (James et al., 2016).
Experimental implant
The titanium single-chamber experimental dental 
implants were designed and manufactured according 
treatments [chemotherapy, radiation therapy, etc. 
(Chen et al., 2013; Kullar and Miller, 2019)], that 
suffer from diseases such as diabetes (Jude et al., 2010; 
Naujokat et al., 2016) or that practice nicotine abuse 
(Hasanoglu Erbasar et al., 2019; Kullar and Miller, 
2019). Patients with such pathologies are considered 
at high-risk for implant therapy (Naujokat et al., 2016) 
and are, thus, often excluded from the beneficial 
implant-related therapeutic treatments, simply since 
bone-forming/healing capabilities are insufficient 
(Hammerle and Tarnow, 2018; Kullar and Miller, 
2019; Obalum et al., 2013) under such conditions.
 The study hypothesis was that if implants 
were placed under such adverse biological 
conditions, in particular under local osteopenic 
(or osteoporotic) conditions, but together with a 
powerful osteoinductive drug (Nam et al., 2017; Shim 
et al., 2018), this would be able to locally overcome 
such healing limitations and actively promote 
angiogenesis (Benn et al., 2017; Pearson et al., 2019) 
and bone formation. In this way, such high-risk 
patients could be converted into low-risk patients and 
more individuals could benefit from the advantages 
of dental implants. If this were the case, then the 
scope of indications for implant treatment could be 
widened.
 A group of drugs that can help overcome such 
biological implant-healing limitations are the 
bone morphogenetic proteins (BMPs) (de Queiroz 
Fernandes et al., 2018; Krishnakumar et al., 2017) that 
both have an angiogenic (Benn et al., 2017; Pearson 
et al., 2019) and osteogenic potential, i.e. are able to 
actively promote bone formation and angiogenesis. 
BMPs, such as BMP-2, are already in clinical use in 
medicine for the treatment of spinal disorders as well 
as impaired fracture healing (non-unions) and have 
led to very successful treatment results (de Queiroz 
Fernandes et al., 2018; Krishnakumar et al., 2017). The 
clinical use of BMPs carries several potential risks, 
leading to drug-induced problems (Bodalia et al., 
2016; Faundez et al., 2016). Such risks are related to 
their use in a free form, in which they are exposed 
locally to many different cell populations (unrelated 
to bone formation) present in the body. This is 
particularly the case when their therapeutic use is 
not restricted, in a more focused application-mode, 
to the specifically targeted cell populations that are 
involved with bone formation and angiogenesis 
processes. Moreover, they are currently used at very 
high dosages, being able, given their pleomorphic 
nature (common to many growth factors), to elicit 
opposite effects depending on the concentration at 
which they reach the target cells (James et al., 2016). 
Given such undesired effects, several slow drug-
release systems have been developed and applied 
for BMPs to reduce the concentrations of the drug 
and to prolong its effects in time (Gruber et al., 2009; 
Liu et al., 2006a; Maisani et al., 2018; Teng et al., 2019; 
Venkatesan et al., 2019). The present study used a BMP 
confined in a carrier that prevented the interaction 
with unintentionally targeted cell populations, thus 
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to a recent study (Hunziker et al., 2018). The single 
cylindrical chamber was 2.1 mm in diameter, 1.3 mm 
in depth (Fig. 1). Thus, the chamber diameter 
approached the critical dimensions for bone-to-
implant gap healing, the critical size [i.e. the chamber 
dimensions were larger than what would allow 
spontaneous bone-to-implant bridging by new bone 
and, thus, spontaneous bony integration in vivo was 
prevented (Botticelli et al., 2003; Harris et al., 1983; 
Hunziker et al., 2018)].
Experimental groups
8 experimental groups were established (Table 1), 
each one consisting of 6 animals. Groups 1, 2 and 3 
comprised titanium implants with standard sand-
blasted, acid-etched chamber surfaces and were 
biomimetically coated with the electrolyte-based 
drug-release system (Liu et al., 2006b). The coating-
carrier material contained incorporated BMP-7 at 
high (group 1), middle (group 2) and low (group 3) 
concentrations. In groups 4, 5 and 6, the sand-blasted, 
acid-etched chamber surface was biomimetically 
coated with the drug-release material in the absence 
of BMP-7. Then, BMP-7 was secondarily adsorbed 
to this coating surface at a high (group 4), middle 
(group 5) or low (group 6) concentration (Hunziker 
et al., 2016). Group 7 implants were biomimetically 
coated with the release system, but no BMP-7 was 
added; group 8 was left uncoated and no BMP-7 was 
added. Each animal received 4 implants according 
to a systematic random distribution protocol; thus, 
per experimental group and per time point 24 and 
8 implants were used, respectively. This resulted in 
a total of 192 implants for the whole experiment, 
comprising a total of 48 animals.
Biomimetic-coating-release system
The implant biomimetic coating was modified to 
function as a drug-release system by depositing 
a bi-layer of electrolytes on the implant surfaces, 
as previously described (Liu et al., 2006b). Briefly, 
the implants were immersed for 24 h at 37 °C 
in concentrated simulated body fluid (Liu et al., 
2006b) under high-nucleation conditions to inhibit 
crystal growth. The thin (1-3 µm-thick) initial 
layer of amorphous CaP deposited on the implant 
surface served as a seeding substratum for the 
subsequent deposition of a thicker layer (35-40 µm-
thick) of crystalline CaP, which served as the drug 
carrier and release system. This second layer was 
prepared by immersing the implants for 48 h at 
37 °C in a supersaturated solution of TRIS-buffered 
(50 mmol/L; pH 7.4) CaP ions, containing the 
desired concentrations of BMP-7 (see below) for 
co-precipitation. The entire coating procedure was 
conducted under sterile conditions.
BMP-7: incorporation, quantification and efficacy 
computation
Human recombinant BMP-7 [also called OP-1 
(Gothard et al., 2014; Kowalczewski and Saul, 2018)] 
was used. The material was obtained as a generous 
gift from the previous Stryker Biotec Corporation 
(a previous subsidiary of the Stryker Corporation, 
Mahwah, NJ, USA). BMP-7 was added to the coating 
solutions at a low, middle and high concentration 
(0.1 μg/mL, 11 μg/mL and 101 μg/mL) such that 
BMP-7 total amount per implant after completion 
of implant coating resulted in 0.23 µg, 4.54 µg and 
17.9 µg, respectively. The quantitative values of these 
carrier-incorporated BMP-7 amounts were obtained 
by using tritium-labelled BMP-7 and subsequent 
quantification of radioactivity after dissolution of 
the carrier coatings obtained by the three different 
concentrations of BMP-7 in the coating solutions 
(Table 1). The adsorbed amounts of BMP-7 were 
obtained by adsorbing defined amounts of BMP-7 
solution to the implant surface and letting them 
dry onto the surface in a sterile hood, such that 
comparable total amounts of adsorbed BMP-7 were 
Fig. 1. Illustration of the experimental dental implant used. (a) Longitudinal section through the implant; 
dimensions are indicated in mm. (b) Image of the implant, illustrating its cylindrical shape, with the large 
single bone chamber for the testing of the osteogenic activity. 
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obtained per implant (0.5µg, 5 µg and 15 µg; Table 
2) in the adsorbed BMP-groups.
 The concentration of BMP-7/g coating material 
was assessed by measuring the total amount of 
BMP-7 incorporated per implant (using a group of 6 
samples) and the carrier (coating) weight per implant, 
measured by weighing the implants after coating 
and again after removal of the coating to obtain the 
total average weight of coating (carrier) material 
per implant. These data delivered the basis for the 
calculations of BMP-7 concentration in the coating 
material. The results obtained were as follows: 29.9 µg 
BMP-7/g coating material (low-dose group), 591.1 µg 
BMP-7/g coating material (middle-dose group) and 
2,330 µg/g coating material (high-dose group). The 
average weight of the coating/implant was 7.68 ± 0.54 
mg [n = 12 implants for coating (carrier) weight].
 In a previous study relating to the coating 
technology, Liu et al. (2006b) determined that the 
incorporation of a growth factor (or a protein, such 
as albumin) leads to a homogenous distribution of 
the compound throughout the coating material, i.e. 
throughout the drug-release system material. On this 
basis, the extent of the coating degradation during 
the experiment when measured at the different time 
points could be used to determine how much BMP-7 
was released during the degradation activity and how 
much was still incorporated in the remaining coating 
volumes. The remaining coating thickness was 
measured at each experimental time point analysed 
and, thus, the amount of BMP-7 liberated during 
each time span of the experiment was determined. 
The information provided yielded the basis for the 
determination of BMP-7 efficacy, i.e. how much bone 
volume was generated per µg of liberated (and thus 
consumed) BMP-7. The calculated BMP-7 efficacy 
values, obtained on this basis, are presented in the 
Results section.
Experimental animals and surgery
A total of 48 adult (2-3 years old) goats, which 
physiologically have osteopenic masticatory bones 
(Caulier et al., 1997), were used. 3 months prior to 
implant placements, 3 left and 3 right premolars 
were surgically extracted from the maxillae of the 
animals. 10 min before surgery, general anaesthesia 
was induced by an intramuscular injection of xylazine 
(20 mg/mL: 0.22 mg/kg of body weight; Lanzhou 
Zhengfeng Pharmaceutical Co. Ltd, Lanzhou, China). 
Then, local anaesthesia of the maxillary sites was 
induced with an injection of lidocaine (20 mg/mL: 
0.83-1.25 mg/kg of body weight in 2.5 mL; Shandong 
Yinhu Pharmaceutical Co. Ltd, Shandong, China). 
After surgically extracting 3 left and 3 right premolars 
from the maxillae of the animals, an intramuscular 
injection of atipamezole (an inhibitor of the α-2 
receptor) (5 mg/mL: 100 μg/kg of body weight; 
Zoetis China, Shanghai, China) was administered 
to accelerate the termination of anaesthesia. At the 
time of surgery and 3 d later, the animals received 
an intramuscular injection of benzylpenicillin 
(150,000 IU/mL: 0.1 mL/kg of body weight; maximally 
5 mL/goat; Hubai Pharmaceutical Co. Ltd., Hubei, 
China). During the first 3 post-operative days, 
analgesics (1 mg/kg Flunixin, Hangzhou Huadi 
Group Co., Ltd., Zhejiang, China) were administered.
 3 months were allowed for the healing of the 
extraction sockets. Then, the implants were inserted 
under the same conditions of general and local 
anaesthesia (as described above). 4 implants were 
inserted into the maxilla (2 on the left side and 2 on the 
right side) of each animal according to a systematic 
random protocol. To assure mutual independence of 
the implantation sites, each implant was separated 
from its neighbours by a minimal distance of 2 mm. 
The implants were inserted according to a standard 
surgical procedure. Intra- and post-operatively, the 
animals were treated as they had been during the 
tooth-extraction procedure (see above). After surgery, 
and up to the time of sacrifice, they were housed at 
a local farm and fed standard goat’s food (forages, 
grains, hay, browse and shrub plants; Web ref. 1). The 
animals were euthanised under general anaesthesia 
by administering an overdose of KCl, which induced 
cardiac arrest.
 The study was approved by the Commission 
for Animal Experimentation of the State of Bern 
(Switzerland) as well as the Ethics Committee of the 
Table 1. Experimental groups.
Groups
Coating BMP-7
Presence (+)/absence (−) Presence (+)/absence (−) Concentration Mode of use
1 + + High Incorporated
2 + + Middle Incorporated
3 + + Low Incorporated
4 + + High Adsorbed
5 + + Middle Adsorbed
6 + + Low Adsorbed
7 + − - -
8 − − - -
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Inner Mongolia Agriculture University (China). It 
was conducted in accordance with the EU Directive 
2010/63/EU on protection of animals used for 
scientific purposes, the ARRIVE guidelines and the 
UK Animals Act (Scientific Procedures) 1986.
Histological processing and sampling
The maxilla of each animal was bisected into its 
left and right halves using a Stryker Orthopaedics 
saw. The soft tissues were removed and excess bone 
around the implants was cut away using an Exakt saw 
(Exakt, Norderstedt near Hamburg, Germany). In 
the mesiodistal direction each tissue block extended 
either to the neighbouring tooth or to the middle 
between the implants. In the buccolingual direction 
the surrounding tissues were included up to the 
natural borders of the mandibula/maxilla. Then, the 
implants were chemically fixed in 4 % formaldehyde 
solution for 10 d at ambient temperature. After 
rinsing in tap water, they were separated from 
each other by using an Exakt saw. The individual 
implants were dehydrated in ethanol and embedded 
in methylmethacrylate, as previously described 
(Hunziker et al., 2007; 2018). Using a Leica saw 
(Leica Microsystems), each implant was sectioned 
in directions that run parallel to its longitudinal axis 
and according to a systematic random sampling 
protocol (Gundersen and Jensen, 1987). Each block 
of methylmethacrylate was cut twice parallel to 
its longitudinal axis at the centre of the implant, 
with a separation distance of 250 µm. Then, the 
approximately 300 µm-thick slices thereby produced 
were cut at right angles to the longitudinal axis of the 
implant. Subsequently, the axial sawing direction for 
the remaining implants was systematically changed 
in increments of 30° such that the orientation of the 
saw-cuts ranged between the mesiodistal and the 
buccolingual directions. Next, the ≈ 300 µm-thick 
saw-cuts were mounted on plexiglass holders, 
polished down to a thickness of about 100 µm and 
surface-stained with basic fuchsin, toluidine blue and 
McNeal’s tetrachrome (Hunziker et al., 2007).
Light microscopy and histomorphometry
The stained saw-cuts were examined using a Nikon 
Eclipse E1000 light microscope (Nikon). If there was 
any evidence of local infection, inflammatory activity 
or a technical artifact in a specimen, it was discarded. 
Primary stability of an implant was a pre-condition 
for its histomorphometric analysis. Sufficient primary 
stability was defined as the existence of minimally 
three points of firm implant anchorage within solid 
native bone. Anchorage within connective tissue was 
considered to be indicative of mechanical instability. 
External to the implant chamber (Fig. 2), the region 
that embraced the interface between the implant and 
the native bone bed was not analysed.
 The peripheral vertical boundary of the implant 
chamber was defined by a virtual, idealised line that 
connected the shoulders of the crestal and the apical 
walls and that ran parallel to the central vertical wall 
(Fig. 2). The boundary between the central vertical 
wall of the chamber and the crestal or the apical walls 
was defined by the point of their intersection, with 
a virtual line that bisected the central corners of the 
chamber at an angle of 45° relative to each face.
 For the evaluation of the BIC-area density along 
the bone chamber surface, the inner chamber surface 
(i.e. the implant chamber space distant from the native 
bone where osteoinduction activity is required to 
form new bone tissue) (Fig. 2b) was analysed. BIC was 
measured using a grid of parallel vertical test-lines, 
which were separated by a fixed distance of 2 mm, 
and by counting the intersection points of the test 
lines hitting bone-implant surface interaction areas.
 The volume density of neoformed mineralised 
bone within the chamber was estimated using the 
point-counting technique (Gundersen et al., 1988). 
Briefly, a grid (intersecting vertical and horizontal 
lines with equal distances from each other) on a 
transparent foil was superimposed on the printed 
histological images. Then, the grid points hitting 
bone tissue versus grid points in the total implant 
chamber space were counted. Next, the quotient of 
the two values represented the estimator for bone 
volume density. The thickness of the remaining 
coating release system was measured by using a set of 
parallel lines, fixed distances apart, and placing them 
perpendicularly to the implant surface with a random 
starting point. The remaining coating thickness 
was measured along the various parallel lines. The 
original coating thickness generated by use of the 
standard chemical coating protocol was measured 
at time point 0 before implantation by using 8 
implants that were coated by the standard protocol 
and then immediately processed histologically for 
the measurement of the original coating thickness.
Table 2. BMP-7 dosages and mode of delivery: incorporated (inc.) or adsorbed (ads.) Average 
coating weight: 7.68 ± 0.54 mg (n = 12).
Delivery mode/dosage BMP-7 per Implant (µg) µg BMP-7/g coating
Inc./High BMP-7 17.9 2330.7
Inc./Middle BMP-7 4.54 591.1
Inc./Low BMP-7 0.23 29.9
Ads./High BMP-7 15 1953.1
Ads./Middle BMP-7 5 651.0
Ads./Low BMP-7 0.5 65.1
CaP-coating alone 0 0
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Statistical analysis
Data are presented as mean values ± standard error 
of the mean (SEM). Differences between estimators 
of experimental groups and time points were 
evaluated by one-way ANOVA and by implementing 
Tukey’s multiple-comparison test (GraphPad Prism 
6, GraphPad Software). Differences between the 
coated and the uncoated specimens were analysed 
using unpaired t-tests. The level of significance was 
set at p < 0.05.
Results
Histomorphometry – new bone volume
The focus of the data description and analysis 
was placed on the formation of new bone in the 
peri-implant chamber space and the coverage of 
the implant surface by new bone, since these two 
parameters represent the key estimators for a 
successful and stable osseointegration and anchoring 
of implants in an osteopenic environment. New 
bone-tissue formation in the peri-implant chamber 
was found to be absent (or minimal) in the first 
week (Fig. 3), except for the group with a low dose 
(0.29 ng) of adsorbed BMP-7, in which a little larger 
bone volume was present (but still less than 0.21 mm3; 
Fig. 3). Fig. 4 shows the time course of peri-implant 
bone volume formation by representative images of 
the BMP-7-incorporated groups. 1 week after surgery 
in the group with the lowest concentration of BMP-
7, no new mineralised bone tissue was present in 
the implant test chamber (Fig. 4a). This finding was 
the same for all experimental groups 1 week post-
operatively (Fig. 3). However, at the end of the second 
week, the formation of new bone tissue was increased 
dramatically (Fig. 4b) and appeared to generally 
stabilise 3 weeks post-operatively (Fig. 4c). The 
groups with low (0.02 ng/g) and middle (2.56 ng/g)-
incorporated dosage as well as low (2.82 ng)-adsorbed 
dosage of BMP-7 showed significantly larger newly 
formed bone volumes in the peri-implant chamber 
space than in all the other groups (Table 2, Fig. 3). 
Thus, during the second week, bone deposition in the 
implant chamber spaces was boosted significantly, 
particularly in the groups in which the low and/or 
the intermediate dosages of BMP-7 were not only 
incorporated into the coating release system, but 
also in the one positive control group in which the 
intermediate dosage of BMP-7 was adsorbed onto the 
coating surface (Fig. 3). In the third post-operative 
week, the group with the lowest incorporated BMP-7 
concentration showed the largest volume of newly 
formed bone tissue. However, bone remodelling 
activities appear to have started, as shown by a 
generally slight decrease in bone volumes at this 
time in several groups, with the maximum value of 
bone being maintained in the incorporated and in the 
adsorbed groups with the lowest concentrations of 
BMP-7 (Fig. 3). The data for bone volumes of these 
two groups differed significantly (p < 0.05) from the 
other groups, where no more increase in bone volume 
occurred. During the further healing process in the 
third week, it became apparent that the formation 
of new bone-tissue volumes plateaued for all (but 
one) group at around 1-1.3 mm3 of new bone in the 
peri-implant chamber. As expected, the variation 
of the results in the osteoporotic environment was 
relatively high, with coefficients of error values being 
in the order of 8-85 %. The one group with the highest 
volume of newly formed bone at the end of the third 
week was the one with the lowest incorporated 
Fig. 2. Light micrographs of histological sections through an implant with a high concentration of 
incorporated BMP-7, three weeks after surgery. (a) The remaining thin CaP coating layer (stained in red), 
bearing BMP-7, could be seen along the implant surfaces (∇). The bone chamber was thoroughly filled with 
new mineralised trabecular bone tissue (m) (also stained in red). Scale bar: 500 µm. (b) The inner part of 
the bone chamber was filled and delineated with a light yellow-shaded colour; it represent the dimensions 
of the bone chamber (given in µm) and the area that was analysed for the quantification of the osteogenic 
activity. Thick sections (80 µm), surface stained with McNeil’s tetrachrome and acid fuchsin. 
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Fig. 3. Bone volumes measured in the various groups represented from the 3 time points investigated. 2 
weeks after surgery, the groups with the incorporated (Inc.) middle and low BMP-7 concentrations and the 
one with the adsorbed (Ads.) middle concentration showed the largest amounts of new bone tissue in the 
bone chambers. 3 weeks after surgery, the group with the low incorporated BMP-7 concentration showed 
the largest newly formed bone volume. Mean values ± SEM are shown. * p < 0.05, ** p < 0.01. 
amount of BMP-7 (0.02 ng/g coating carrier) and 
revealed around 1.8 mm3 of newly formed bone. This 
value was significantly different when compared 
to the implant-alone group and to the middle and 
high BMP-7-incorporated groups. Due to the large 
variances in the osteoporotic environment, the 
p-values compared to the remaining groups were in 
the range of 0.06-0.08.
 The groups without a CaP-coating carrier or 
without BMP-7 were generally found to have 
the smallest bone volumes (Fig. 3). Interestingly, 
however, the groups with higher concentrations of 
incorporated BMP-7 (middle and high concentrations) 
showed newly formed bone volumes in the same 
order of magnitude as those groups with BMP-7 
adsorbed to the CaP coating carrier surface, at least 3 
weeks post-operatively. 2 weeks post-operatively, the 
bone volumes for these groups varied considerably. 
It is noteworthy that the group with a CaP-coating 
alone without BMP-7 showed a larger bone volume 
than the group without any coating (metal surface: 
sand-blasted and acid etched) and the volume of 
newly formed bone of the CaP-coated group was in 
the same order of magnitude as the remaining BMP-7 
groups.
 The morphological-descriptive results of the other 
groups were similar, as illustrated in Fig. 4 by selected 
representative images.
Implant surface coverage by bone (BIC)
Newly formed bone could be identified along the 
chamber walls, particularly on the CaP-coating carrier 
layer, which had a strong osteoconductive effect 
(Fig. 5). 3 weeks after surgery, the group with the 
lowest incorporated BMP-7 concentration showed the 
highest BIC value. However, this value did not differ 
significantly from the adsorbed middle-concentration 
group (p > 0.05), with the highest BIC value 2 weeks 
post-operatively (Fig. 5).
 A particularly interesting finding was that the 
CaP-only group showed a bone coverage result in the 
order of 40 %, i.e. very similar to the BMP-7 groups 
(irrespective if adsorbed or incorporated). Moreover, 
the metal-surface-only group clearly showed a 
significantly lower BIC value when compared to all 
the other experimental groups (Fig. 5), both 2 and 3 
weeks post-operatively.
 It is noteworthy that by the end of the third post-
operative week, the BIC value was the highest in 
the group in which the lowest dosage of BMP-7 was 
incorporated into the coating and in the group with 
the intermediate dose of surface-adsorbed BMP-7. 
Interestingly, the second-higher dose of adsorbed 
BMP-7 was associated with a significant drop in 
the BIC value obtained (p < 0.05), pointing out the 
critical role of BMP-7 dosage for optimal surface 
osteoconductive effects.
BMP-7 release and efficacy
The measurement of the coating degradation, i.e. 
the initial mean coating thickness minus the coating 
thickness at the end of the first, second and third 
week, revealed that in the first 2 weeks carrier 
coatings were degraded by about 60-70 % and that 
the degradation process continued in the third 
week so that about 70-85 % of the coatings became 
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degraded in all groups (data not shown). Based on 
the data obtained for coating carrier degradation 
and BMP-7 concentrations in the coating, BMP-7 
release per time interval (first, second, third week) 
could be computed. The efficacy of BMP-7, which 
was defined as the volume of bone formed per µg of 
BMP-7 liberated from the coating carrier, was found 
to be highest in the group in which the lowest BMP-7 
dosage was incorporated into the release system. This 
efficacy index was calculated based on the coating 
thickness at the end of each time period (Fig. 6). Data 
revealed that the efficacy of BMP-7 was clearly and 
significantly the highest in the group with the lowest 
incorporated BMP-7 concentration: in the second 
week, it was around 234 mm3 of new bone per µg of 
liberated BMP-7; in the third week, around 103 mm3 
of new bone per µg of liberated BMP-7 (Fig. 6). Thus, 
higher BMP-7 efficacy values were achieved by its 
lowest concentration; the efficacy of BMP-7 in this 
group was found to be roughly 65 to 170 times higher 
than in the other BMP-7 groups.
Systematic morphology and adverse effects
Systematic histological analyses were performed 
throughout and around the implants (i.e. in close 
vicinity; Fig. 2,4) and in distant regions (i.e. to the 
natural mandibular/maxillar border in the bucco-
medial direction; see Materials and Methods 
section). Systematic serial vertical sectioning 
generally provided 4 parallel sections per tissue 
block and were scanned at higher magnifications. 
This scanning analysis revealed no evidence of any 
BMP-7-induced adverse effects at, near or distant to 
the implantation sites. In particular, unwanted effects 
such as cyst formation, local tissue swellings, ectopic 
ossification, immunological responses, malignant cell 
transformation, etc. (Faundez et al., 2016; Hudolin et 
al., 2020; Malham et al., 2015) were not found.
Discussion
New bone-tissue formation in the implant chamber 
under an osteopenic condition [as a paradigm for any 
state of local lack of bone tissue (such as osteoporosis, 
atrophy etc.) or impaired angiogenesis (which is 
associated with reduced formation of new bone 
tissue)] was impressively accelerated in the second 
post-operative week and it attained a large new 
bone volume by the lowest concentration of BMP-
7 delivered by the slow drug-release system. The 
narrow span of BMP-7 concentrations found to yield 
optimal results (compared to higher concentrations in 
the slow-release system and/or to adsorbed BMP-7 at 
slightly higher concentrations) nicely illustrated the 
importance of a strict control of drug concentration, 
which is needed for a safe and efficient BMP-7 use; 
otherwise, the desired effects may not be achieved 
or may even be counteracted. Even though a few 
experimental groups were associated with the 
formation of new bone tissue at a similar level and on 
a similar time scale to that of the low-concentration-
incorporated group, the important fact to be noted 
was that when the growth factor was sequestered 
away from the many implant-surrounding different 
cell populations (as is the case when using a slow-
release system), the danger of unwanted side effects 
was indeed minimal. Moreover, if the growth factor 
is not incorporated in a slow-release system, the 
reservoir of the drug would be exhausted as rapidly 
as e.g. in the surface-adsorbed growth factor pool 
or in a freely applied mode of delivery [as is done 
presently in clinical practice (Burkus et al., 2003; 
Sierra-Garcia et al., 2016)]. In addition, a sustained 
release over time from a confined compartment not 
only assures a long-term ongoing osteogenic activity, 
but also provides maximum efficacy (being the 
delivery system directed specifically to the targeted 
cell pools) as well as mimics the physiological mode 
Fig. 4. Light micrograph of representative 
histological sections through implants from the 3 
different post-operative time points investigated. 
(a) Adsorbed middle concentration of BMP-2, 1 week 
after surgery, with no newly formed bone tissue 
present. (b) Low concentration of incorporated 
BMP-7, 2 weeks after surgery: a rapid increase of 
newly formed bone tissue could be identified. (c) 
Low concentration of incorporated BMP-7, 3 weeks 
post-operatively: larger volumes of newly formed 
bone tissue were present. Thick sections (80 µm), 
surface-stained using McNeil’s tetrachrome and acid 
fuchsin. Scale bars: 200 µm. 
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of growth factor release from the bone matrix during 
bone remodelling (Liu et al., 2018; Liu et al., 2005).
 Other approaches to deal with the enhancement 
and acceleration of bone formation and implant 
osseointegration under osteopenic/osteoporotic 
conditions have been described, such as the local 
delivery of BMP-4 (Lai et al., 2011), the use of injectable 
tricalcium phosphate (TCP)-microspheres associated 
with BMP-2 (Chang et al., 2017), the local application 
of anti-cytokine antibodies (Yang et al., 2020) or the 
use of systemic sclerostin antibody treatment (Korn 
et al., 2019; Virdi et al., 2015). Another approach 
suggested relates to the presurgical injection of 
BMP-7 in a slow-release system [polyglycolic acid 
(PLGA)-microspheres] to initially build up local bone 
structure before implant placement (Phillips et al., 
2006).
 The concentration of BMP-7 identified in the 
present study for a maximum efficacy (≈ 30 µg BMP-
7/g carrier material) and for maximum osteogenicity 
(i.e. the largest volumes of new peri-implant bone 
tissue) was of the same order of magnitude as 
found by Hunziker et al. (2016) for BMP-2. BMP-2 
was tested in sheep bones in vivo in a normal bony 
environment, using thick titanium-mesh implants 
for deep implant anchoring to the bone (such as 
cups of hip prostheses, etc.). The reason for this 
could be that both growth factors (BMP-2 and BMP-
7) were used at a very low dose, in the order of 
magnitude of BMPs’ physiological concentrations, 
as stored in the healthy bone matrix. Such doses are 
physiologically released by a cell-mediated process 
during normal bone remodelling activities, during 
bone healing events such as bone fractures or healing 
of artificially created bone wound surfaces, such as 
during implant placement. In addition, the high 
degree of BMP-based osteogenicity may be due to 
the mechanism of release associated with such a 
CaP-based carrier matrix, simulating a native bone 
matrix from which the growth factor is released 
on a cell-mediated basis (Liu et al., 2018). Thus, the 
simulation of a physiological-like cell-mediated 
BMP release mode may be associated with a much 
higher efficacy than when applied therapeutically 
as a free factor or simply as an adsorbed factor to 
a carrier – which is in neither case a physiological 
mode. Moreover, by slow releasing the growth factor, 
the targeted cell pool is specifically the one involved 
in osteogenesis and the drug is not dispersed omni-
directionally onto different cell pools not involved in 
osteogenesis, but it remains confined and specifically 
exposed to the osteogenic cell-pool niche. Given the 
fact that this growth factor is highly pleiomorphic 
by its very nature, i.e. it is able to simultaneously 
induce both bone resorption and bone formation, 
its concentration in the physiological environment 
at a near-physiological level may be the key factor 
in the intrinsic decision to tipping the balance either 
towards a resorption activity (catabolic) or towards 
a formation activity (anabolic) (Herberg et al., 2014; 
Hunziker et al., 2016; Pobloth et al., 2017). Thus, the 
general problems associated with the clinical use of 
Fig. 5. Bone-to-implant contact proportions (BIC-values) in the various groups at the 3 time points 
investigated are represented. 1 week after surgery, all BIC-values obtained were very low. 2 weeks after 
surgery, the groups with the adsorbed (Ads.) middle BMP-7 concentration and the CaP-control group 
without any BMP-7 showed the highest BIC values. 3 weeks after surgery, the groups with the incorporated 
(Inc.) BMP-7 at low concentration and the group with the adsorbed middle concentration of BMP-7 showed 
the highest BIC-values. Mean values ± SEM are represented . * p < 0.05, ** p < 0.01.
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this growth factor are indeed associated with its use at 
unphysiological high dosages at which it is generally 
applied (mg-levels) and the unphysiological mode 
by which it is exposed to the complex body cellular 
environment, i.e. to a variety of cell pools not involved 
in osteogenesis, both under physiological (normal 
bone) or pathological (osteoporosis, osteopenia, 
metabolic bone diseases, fractures, etc.) conditions.
 Another aspect to be pointed out by using 
such a slow drug-release system is the fact that 
this drug carrier system has a thickness/mass that 
can be modulated (Liu et al., 2006b) to have longer 
degradation times and, thus, longer release and 
osteogenic induction times, if desired (Liu et al., 
2018). This property could be a practical necessity, 
in particular when used under osteoporotic or 
osteopenic conditions or in situations where 
extensive bone augmentation is a clinical need. Also, 
in situations where a very long-lasting mechanical 
stability is needed to be actively induced such as, 
for example, under osteoporotic conditions where a 
long-lasting local anabolic osteogenic effect would 
be very welcome. Such possibilities render the CaP-
based drug carrier system particularly versatile and 
flexible to satisfy disease-specific needs.
 The focus of the present study was intentionally 
set towards the new peri-implant bone volume 
formed rather than on the BIC parameter, i.e. the 
surface coverage of the implant with a thin layer 
of bone tissue. This latter phenomenon is primarily 
the result of and associated with a high degree of 
implant surface osteoconductive property (Liu et al., 
2007). The firm and rapid anchoring of the implant 
requires a bridging of the whole implant surface to 
the native bone surface distant (peripheral) to it. It 
is this gap space that needs to be filled as rapidly 
and as evenly as possible with newly formed bone 
for the purpose of effective load force transmission 
from the implant to the native bone structure during 
implant loading activity. Only the presence of such 
bony bridging masses can provide a solid and 
firm secondary stability outcome for the implant 
(Bianchi et al., 2005; Cozzolino et al., 2019; Kopp 
et al., 2011). The mere coverage of the implant 
surface by a thin layer of bone tissue (as generally 
described by the BIC parameter), which is due to 
high osteconductive surface properties, is indeed 
insufficient in providing the necessary anchoring 
and functional osseointegration for a required 
biomechanical competence of the whole implant. The 
required rapid and homogenous gap-bridging by 
newly formed bone tissue between the native bone 
surface and the implant surface can be assessed only 
by measuring the newly formed bone tissue volume 
in this gap [and not by a simple parameter such as 
BIC (Hunziker et al., 2018), which unfortunately is 
often used in various studies relating to implant 
integration, with its biological meaningfulness thus 
overinterpreted]. The importance of a mechanically 
firm and even osseous connectivity between the 
implant surface and the surrounding native bone 
surfaces, in the orthopaedic implant development 
Fig. 6. Computed efficacy of BMP-7, defined as new bone volume generated per µg liberated BMP-7. Only 
2 weeks after surgery a measurable efficacy was observed, with the incorporated (Inc.) low concentration 
BMP-7 group showing the highest efficacy values, compared to all remaining groups. Mean values ± SEM 
are represented. ** p < 0.01. Ads.: adsorbed.
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process, was realised several decades ago when Bill 
Harris coined the term “osteogenic jumping distance” 
(Harris et al., 1983), which is nowadays called “critical 
gap healing distance” between native bone and 
implant surface (Alierta et al., 2014; Botticelli et al., 
2003; Moreo et al., 2009).
 It is not surprising that the osteoconductive 
surface properties that govern the BIC effects are 
independent of the presence and/or absence of BMP-
7. It is the CaP surface itself that is able to enhance 
the osteoconductive effects alone (and improve BIC 
values), as previously shown (Liu et al., 2007). But, 
unfortunately not enough attention is paid to the 
fact that the space between implant surfaces and 
native bone surfaces needs to be filled very rapidly, 
which can be quite challenging in particular under 
pathological conditions of insufficient bone tissue 
density (osteoporosis, osteopenia, etc.) or under 
conditions of angiogenesis problems, such as under 
nicotine abuse, diabetes etc.. The data of the present 
study reconfirmed previous findings: an implant 
surface with an enhanced osteoconductive property 
yields higher BIC values than simple SLA-titanium 
surfaces and the presence of BMPs additionally 
improves the peri-implant bone volume generated 
over just a simply enhanced osteoconductive surface 
property (Liu et al., 2007).
 The systematic histological analyses of the peri-
implant tissues close to and also distant from the 
implant surfaces (Fig. 2,4) revealed no evidence of any 
BMP-7-induced adverse effects at or near the implant 
sites. Unwanted effects such as cyst formation, tissue 
swelling, ectopic ossification, etc. (Krishnakumar et 
al., 2017) were not observed. This most likely related 
to the relatively low concentrations of BMP used in 
all test groups; even those with a higher concentration 
of BMP and when used in an adsorbed form to the 
implant or carrier surfaces showed no complications 
of this type [since these concentrations were still 
orders of magnitude lower than what is applied 
in clinical practice (Pobloth et al., 2017)]. Indeed, in 
clinical practice, where various types of unwanted 
effects are observed, these are consistently associated 
with the use of BMPs on a mg-dosage level (Pobloth 
et al., 2017). In addition, the growth factors remained 
sequestered away from the various cell pools not 
involved in osteogenesis by using a delayed drug-
release system. Such a system confines them spatially 
and the factor is released on a cell-mediated basis 
(Liu et al., 2018) and, hence, is targeted to the desired 
osteogenesis-related cell pools.
 Several limitations of the ruminant-animal model 
cannot be avoided since they are inherent to this 
model and relate to an immediate implant-loading 
scheme after surgery, combined with an exposure 
to high local masticatory stress forces (that cannot 
be avoided either). Thus, it was no surprise that 8 
implants showed an insufficient primary stability 
(as defined by the criteria described in the Materials 
and Methods section). The reduced primary implant 
stability in an osteoporotic bone environment 
certainly has also contributed to this loss of implants. 
Moreover, in adult goats, local post-operative 
dental hygiene is not possible (for practical reasons) 
and, thus, 6 implants were found to show local 
infections. These contaminated implants as well as 
the mechanically unstable implants were excluded 
from the analysis. Also 3 animals were lost due to 
acute lethal diseases of unknown origin.
 There is no doubt that this animal model has its 
disadvantages as these losses of implants do point 
out. However, what would be the alternative? The 
induction of osteoporosis in adult sheep (or dogs) is 
medically quite an aggressive procedure, including 
ovariectomy and steroid hormone application over 
several months, such as is done in the well-known 
osteoporosis sheep model (Kielbowicz et al., 2016; 
Zhang et al., 2016). Moreover, this model requires 
a preparation time of almost one year that would 
render the study extremely expensive, but also 
introduce some changes in the body physiology 
[absence of the normal female sex hormones, 
depression of metabolism due to chronic steroid 
application, model-induced impaired bone formation 
capabilities (Egermann et al., 2005; Zhang et al., 2016)] 
that would limit the conclusion potential of the study. 
Thus, this physiological model of local osteopenia 
(structurally appearing as in osteoporosis) was 
assumed to be useful since little secondary changes 
to the general metabolism were operating when 
compared to the experimentally induced animal 
models for osteoporosis.
Conclusion
BMP-7 was found to be a highly efficacious drug in 
actively promoting and accelerating the formation 
of new bone in the peri-implant space in a hostile 
osteopenic environment if released slowly over 
time at near-physiological concentrations. The use 
of a delayed drug-delivery system allowed for 
minimalisation of the required osteogenic growth 
factor dosage and was able to prevent untoward side-
effects (ectopic bone formation, inflammation, cyst 
formation etc.) by warding off the bioactive agent and, 
thus, significantly enhancing the safety of this drug.
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Piefrancesco Pagella: Did the authors observe 
alterations in the degree of vascularisation or immune 
reaction in response to the different experimental 
conditions?
Authors: The authors verified only morphologically 
if any cell-based unwanted immune responses 
were present and such responses were not found. 
Humoral and other blood-borne immunological 
analyses were not performed. Moreover, possible 
different degrees of vascularisation in the different 
experimental groups at the end of the experiment 
were not studied. Indeed, this may be an interesting 
aspect to be investigated and may help to reinforce 
data interpretation. It is also clear that since in all 
experimental groups the same type of animals were 
used, no differences in vascularisation could be 
expected at the onset of the experiments. And since 
newly formed bone tissue is always associated with 
the presence of blood vessels (it is a precondition of 
bone tissue formation), in the experimental groups 
with larger bone volume densities at the end of the 
experiment also the associated blood vasculature was 
increased in parallel.
 The experimental set up was designed to 
investigate the possible enhancement of the process 
of new bone formation in the early phase of healing 
of dental implants under osteopenic conditions. To 
study the healed implant maintenance duration and 
the long-term survival, a full new study would need 
to be performed.
Editor’s note: The Scientific Editor responsible for 
this paper was Thimios Mitsiadis.
